as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹37.3
Change
+5.65 (17.85%)
Open
₹31.8
Prev. Close
₹31.65
Day High
₹37.98
Day Low
₹31.8
Volume Analysis
Traded
3,270,918
Delivered
1,016,627
Delivery %
31.08%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •Low return on equity (0.59%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (36/100)
- •Low operating margin (4.3%)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹45.76 | ₹41.87 | ₹39.58 | ₹35.69 | ₹33.4 | ₹29.51 | ₹27.22 |
| Fibonacci | ₹41.87 | ₹39.51 | ₹38.05 | ₹35.69 | ₹33.33 | ₹31.87 | ₹29.51 |
| Camarilla | ₹39.0 | ₹38.43 | ₹37.87 | ₹35.69 | ₹36.73 | ₹36.17 | ₹35.6 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+31.85%
1 Week
+56.46%
1 Month
+76.78%
3 Months
+66.52%
6 Months
+48.84%
1 Year
+3.67%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
0.0%
Net margin 0.98% × asset turnover 0.0x × equity multiplier 1.0x
Company Overview
Sector
Healthcare
Market Cap
₹175 Cr
P/E (TTM)
51.8
ROE
0.59%
Book Value
₹46.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Balaxi Pharma Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 36/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (0.59%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
36/100 — WeakData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Stock is trading at 0.69 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of 3.15% over past five years.
- −Company has a low return on equity of -3.58% over last 3 years.
- −Company has high debtors of 184 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Q2/H1 FY27 investor presentation: revenue rose 39.4% to ₹80.5 crore in Q2; Jadcherla facility now operational.
Published unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.
Q2 FY27 revenue rose 45% to ₹81.37 crore; EBITDA up 338%, PAT up 450%; Jadcherla facility operational.
Board approved Q2 FY26 results and noted WHO-GMP certification; Jadcherla plant now has 34 approved products.
Q2 FY26 results approved; Jadcherla plant received WHO-GMP certification, producing 22 products with 34 approved.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 55 | 61 | 60 | 66 | 77 | 73 | 76 | 71 | 56 | 73 | 71 | 81 | 81 |
| Expenses + | 44 | 47 | 46 | 56 | 67 | 69 | 64 | 67 | 55 | 69 | 71 | 76 | 76 |
| Operating Profit | 11 | 14 | 13 | 10 | 11 | 4 | 13 | 4 | 1 | 3 | 0 | 5 | 5 |
| OPM % | 19.66% | 22.45% | 22.51% | 15.38% | 13.69% | 5.44% | 16.45% | 5.88% | 2.06% | 4.26% | 0.17% | 5.78% | 6.3% |
| Other Income + | 6 | 2 | -1 | -2 | -4 | 4 | -2 | -2 | 2 | 0 | 3 | -1 | -1 |
| Interest | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 16 | 14 | 11 | 7 | 6 | 6 | 10 | 1 | 1 | 2 | 1 | 2 | 2 |
| Tax % | 7.92% | 4.77% | 4.87% | 12.06% | 17.41% | 11.7% | 10.56% | 67.03% | 84.06% | 80.75% | 56.43% | 38.28% | 43.07% |
| Net Profit + | 14 | 14 | 11 | 6 | 5 | 5 | 9 | 0 | 0 | 0 | 1 | 1 | 1 |
| EPS in Rs | 3 | 3 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -37 | -30 | -26 | -1 | 41 | 21 | 27 | 8 | -27 | -1 | -7 | 14 | 45 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 0 | 0 | 0 | 14 | 46 | 231 | 279 | 336 | 241 | 293 | 270 | 305 |
| Expenses + | 0 | 0 | 0 | 1 | 12 | 37 | 189 | 229 | 279 | 197 | 254 | 261 | 292 |
| Operating Profit | 0 | 0 | 0 | -1 | 2 | 8 | 43 | 51 | 57 | 45 | 38 | 10 | 13 |
| OPM % | 33.0% | -120.0% | — | — | 11.0% | 18.0% | 18.0% | 18.0% | 17.0% | 18.0% | 13.0% | 3.5% | 4.3% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 5 | 3 | -38 | -4 | 3 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 5 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 0 | 0 | 0 | -1 | 2 | 9 | 44 | 55 | 57 | 2 | 29 | 5 | 7 |
| Tax % | 27.0% | -36.0% | 0.0% | 0.0% | 19.0% | 31.0% | 14.0% | 13.0% | 19.0% | 219.0% | 13.0% | 73.0% | — |
| Net Profit + | 0 | 0 | 0 | -1 | 2 | 6 | 38 | 48 | 46 | -2 | 25 | 1 | 3 |
| EPS in Rs | 0 | 0 | 0 | -1 | 1 | 1 | 8 | 10 | 9 | 0 | 5 | 0 | 1 |
| Dividend Payout % | 91.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | -14 | -58 | -100 | — | — | 236 | 407 | 21 | 20 | -28 | 21 | -8 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 0 | 0 | -1 | -1 | 0 | 18 | 55 | 103 | 173 | 190 | 221 | 238 | 243 |
| Borrowings + | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 13 | 19 | 53 | 58 | 52 |
| Other Liabilities + | 0 | 0 | 0 | 0 | 3 | 8 | 31 | 60 | 43 | 38 | 25 | 30 | 36 |
| Total Liabilities | 4 | 4 | 2 | 2 | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 | 341 |
| Fixed Assets + | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 29 | 41 | 41 | 41 | 82 | 82 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 22 | 0 | 0 |
| Investments | 3 | 3 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 0 | 0 | 2 | 2 | 6 | 36 | 94 | 147 | 195 | 215 | 247 | 255 | 259 |
| Total Assets | 4 | 4 | 2 | 2 | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 | 341 |
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 0 | 0 | -1 | -2 | -14 | 0 | 34 | 6 | 5 | -35 | -4 |
| Cash from Investing Activity + | -3 | 0 | 3 | 0 | 0 | 0 | -6 | -28 | -11 | -1 | -22 | -21 |
| Cash from Financing Activity + | 2 | 0 | 0 | 0 | 0 | 18 | 4 | 0 | 26 | 30 | 34 | 0 |
| Net Cash Flow | -1 | 0 | 2 | -1 | -2 | 4 | -2 | 6 | 21 | 34 | -23 | -25 |
| Free Cash Flow | 0 | 0 | 0 | -1 | -2 | -14 | -3 | 7 | -9 | 4 | -57 | -25 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 700 | 50 | 100 | 88 | -97 | -161 | 6 | 78 | 32 | 26 | -83 | 2 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 10.18% | 15.91% | 17.11% | 17.5% | 17.5% | 17.96% | 25.12% | 30.49% | 32.24% | 31.45% | 31.45% | 31.45% |
| Promoters | 71.22% | 66.86% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% |
| FII | 18.57% | 17.21% | 16.88% | 16.48% | 16.48% | 16.02% | 8.87% | 3.5% | 1.74% | 0.0% | 0.0% | 0.0% |
| DII | 0.03% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 2.56% | 2.56% | 2.56% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Balaxi Pharma Ltd (this stock) | 175 | 51.8 | 0.69 | 0.59% |
| Makers Laboratories Ltd. | 169 | 22.6 | 2.15 | 3.17% |
| Take Limited | 192 | 22.0 | 5.6 | 16.5% |
| Nectar Lifesciences Ltd. | 193 | — | 0.34 | -31.3% |
| Bilcare Ltd. | 202 | 5.55 | 1.13 | 1.39% |
| Brooks Lab Limited | 203 | 58.7 | 1.08 | 22.0% |
| Natural Capsules Limited | 144 | — | 0.66 | -9.45% |
Which Mutual Funds Hold Balaxi Pharma Ltd?
Frequently Asked Questions about Balaxi Pharma Ltd
Balaxi Pharma Ltd (BALAXI) closed at ₹37.3 on NSE on 19 November 2026, up 5.65 (17.85%) from the previous close.
Balaxi Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol BALAXI.
Balaxi Pharma Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 51.8.
Balaxi Pharma Ltd has a dividend yield of 0.0%.
Balaxi Pharma Ltd's 52-week high is ₹41.0 and its 52-week low is ₹15.2.
Balaxi Pharma Ltd has a market capitalisation of ₹175 crore.
Balaxi Pharma Ltd has a TopFund Quality Score of 36/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Balaxi Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.